Designing a platform technology ofr age appropriate pediatric dosage form
By: More, D. M
.
Contributor(s): Chaudhari, P. D.
Publisher: Mumbai Indian Drug Manufacture's Association - IDMA 2019Edition: Vol.56(5), May.Description: 14-23p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian drugsSummary: Present work was aimed to develop a platform technology for pediatric dosage form which masks the bitter taste of a drug and to prepare flexible solid oral dosage form using hot melt extrusion (HME). Eudragit EPO, a cationic co-polymer insoluble in pH above 5, was used as a taste masking polymer to restrict the drug release in saliva. Soluplus, a graft co-polymer freely soluble in water was used as solubility enhancer. Test formulation released less than 10 % drug Tenofovir Disoproxil Fumarate (TDF) in pH 6.8 compared to 89% of marketed formulation simulated to limited release of drug in the saliva and thus avoiding the bitterness. DSC and XRD tests confirmed the existence of molecularly dispersed drug. FTIR confirmed the presence of unchanged functional groups of drug in its tablet form after HME processing. Proposed platform technology successfully masked the bitter taste in the ratio of D:P 1:2 and overcame this challenge of oral dosage form.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2020649 |
Present work was aimed to develop a platform technology for pediatric dosage form which masks the bitter taste of a drug and to prepare flexible solid oral dosage form using hot melt extrusion (HME). Eudragit EPO, a cationic co-polymer insoluble in pH above 5, was used as a taste masking polymer to restrict the drug release in saliva. Soluplus, a graft co-polymer freely soluble in water was used as solubility enhancer. Test formulation released less than 10 % drug Tenofovir Disoproxil Fumarate (TDF) in pH 6.8 compared to 89% of marketed formulation simulated to limited release of drug in the saliva and thus avoiding the bitterness. DSC and XRD tests confirmed the existence of molecularly dispersed drug. FTIR confirmed the presence of unchanged functional groups of drug in its tablet form after HME processing. Proposed platform technology successfully masked the bitter taste in the ratio of D:P 1:2 and overcame this challenge of oral dosage form.
Click on an image to view it in the image viewer
There are no comments for this item.